NCT05429840View on ClinicalTrials.gov

Safety & PK of Single Doses of MT1980

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

October 4, 2022

Study Completion Date

October 4, 2022

Conditions
Neuroinflammatory Response
Interventions
DRUG

MT1980

single dose

DRUG

Placebo

single dose

Trial Locations (1)

Unknown

Icon Early Development Services, Groningen

Sponsors

Collaborators (1)

ICON plc
All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Monument Therapeutics Limited

INDUSTRY